Humanetics Corporation

Updates on the development of Humanetics Corporation’s (Humanetics) new drug candidate, BIO 300, were presented at the 2024 Military Health System Research Symposium (MHSRS), held August 26-29th in Kissimmee, Florida. MHSRS is the U.S. Department of Defense’s (DOD) foremost scientific meeting focusing on the unique medical needs of warfighters. #radiationprotection #medicalcountermeasure Follow this link to learn more: https://lnkd.in/gvVFYSRE

Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and cancer patients, will discuss BIO 300, its promising lead radioprotective drug candidate, at the BIO Investor Forum, Oct. 15-16, 2024. This event showcases drug development programs ready for partnering or venture funding, focusing on accelerating new therapeutic technologies into commercialization. It features panel discussions on policy, business, financing, and R&D, along with company presentations and BIO One-on-One Partnering™ meetings. The 2023 forum hosted over 1,600 partnering meetings. The conference takes place at the Fairmont Hotel in San Francisco. #radiationprotection #medicalcountermeasure #oncology Follow this link to learn more: https://lnkd.in/gnM2HZkH

We're #hiring a new Research And Development Scientist in Minneapolis, Minnesota. Apply today or share this post with your network.

Humanetics Corporation, in collaboration with researchers within the U.S. Department of Defense at the Armed Forces Radiobiology Research Institute, has entered into a new $3 million cooperative research agreement to continue advanced development of BIO 300, a medical countermeasure to protect military personnel and civilian first responders from harm caused by radiation exposure. #radiationprotection #radiation #medicalcountermeasure Follow this link to learn more: https://lnkd.in/dGxTEQ8b

Ronald J. Zenk, President and Chief Operating Officer of Humanetics will present at the prestigious Biotechnology Innovation Organization (BIO) International Convention in San Diego, CA on Monday, June 3, 2024 (1:30PM Company Presentation Theatre 3). #oncology #radiationoncology #radiationprotection Follow this link to learn more: https://lnkd.in/gybp2c3i

📣 We’re thrilled to welcome Humanetics Corporation, an innovator in the prevention of harmful effects from radiation, to our portfolio! We are excited to join our US-based angels in supporting Ronald Zenk and the team in this next phase of growth! 🚀 Visit www.humaneticscorp.com to find out more and reach out if you’d also like to get funded: [email protected]. #KeiretsuBacked

We're #hiring a new Quality Specialist in Minneapolis, Minnesota. Apply today or share this post with your network.

Ronald J. Zenk, President and Chief Operating Officer of Humanetics and Dr. Colin Chin, Chief Medical Officer presented at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, on February 13th (virtual). This conference provides investors with a broad spectrum of public and private healthcare companies spanning all major sectors of the healthcare industry. Mr. Zenk and Dr. Chin presented BIO 300, a new drug candidate focused on improving outcomes in cancer radiotherapy by protecting normal tissues from radiation damage. BIO 300 is also being developed for use by the Department of Defense to protect warfighters from radiation exposure. Their presentation can be viewed with link below. #oncology #radiationoncology #radiationprotection

Ronald J. Zenk, CEO of Humanetics Corporation will be presenting today to the Emerging Growth Conference at 1:45pm Eastern. The Emerging Growth Conference features companies in a wide range of growth sectors with strong management teams, innovative products and services, and focused strategy and execution. The potential audience includes tens of thousands of individual and institutional investors, investment advisors, and analysts. Follow this link for access to the webcast: https://lnkd.in/ggjYsNxw 

We're #hiring a new Quality Specialist in United States. Apply today or share this post with your network.